Literature DB >> 23069858

Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy.

N Simon1, A Marsot, E Villard, S Choquet, H-X Khe, N Zahr, P Lechat, V Leblond, J-S Hulot.   

Abstract

Human multidrug resistance-related protein 2 (MRP2, encoded by ABCC2) is involved in the transport of anionic drugs such as methotrexate (MTX). We prospectively investigated the influence of four common ABCC2 genetic variants (rs717620, rs2273697, rs8187694 and rs8187710) on MTX pharmacokinetics parameters. MTX concentrations were monitored in 50 patients with lymphoid malignancy (27 males; mean age: 53±17 years) receiving high-dose MTX (5.13±1.88 g m(-)(2) in a 4-h perfusion). The population pharmacokinetics modelling showed that ABCC2 -24T allele (rs717620) had a combined influence on both MTX elimination and distribution. The MTX clearance and distribution volume were significantly higher in carriers of at least one copy of the -24T allele as compared with noncarriers: 8.6±2.2 vs 6.7± 2.5 l h(-1), P<0.01 and 30.7±7.7 vs 22.1±8.8 l, P<0.001, respectively. Consequently, -24T allele carriers were more prone to reach MTX nontoxic levels, 48 h after administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23069858     DOI: 10.1038/tpj.2012.37

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  10 in total

1.  Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters.

Authors:  Ahmed Nader; Noran Zahran; Aya Alshammaa; Heba Altaweel; Nancy Kassem; Kyle John Wilby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

2.  High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next?

Authors:  Hala O El Mesallamy; Wafaa M Rashed; Nadia M Hamdy; Nayera Hamdy
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-10       Impact factor: 4.553

3.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 4.  The intestinal absorption of folates.

Authors:  Michele Visentin; Ndeye Diop-Bove; Rongbao Zhao; I David Goldman
Journal:  Annu Rev Physiol       Date:  2014       Impact factor: 19.318

5.  Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?

Authors:  Aurea Lima; Miguel Bernardes; Rita Azevedo; Rui Medeiros; Vítor Seabra
Journal:  Int J Mol Sci       Date:  2015-06-16       Impact factor: 5.923

6.  Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.

Authors:  Yan Liu; You Yin; Qi Sheng; Xiaotong Lu; Fang Wang; Zhiyan Lin; Huaiping Tian; Ajing Xu; Jian Zhang
Journal:  PLoS One       Date:  2014-01-03       Impact factor: 3.240

7.  Evaluation and Application of Population Pharmacokinetic Models for Identifying Delayed Methotrexate Elimination in Patients With Primary Central Nervous System Lymphoma.

Authors:  Junjun Mao; Qing Li; Pei Li; Weiwei Qin; Bobin Chen; Mingkang Zhong
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

8.  Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.

Authors:  Usman Arshad; Max Taubert; Tamina Seeger-Nukpezah; Sami Ullah; Kirsten C Spindeldreier; Ulrich Jaehde; Michael Hallek; Uwe Fuhr; Jörg Janne Vehreschild; Carolin Jakob
Journal:  BMC Cancer       Date:  2021-06-20       Impact factor: 4.430

9.  Anti-tumor Study of Chondroitin Sulfate-Methotrexate Nanogels.

Authors:  Jinyu Wang; Weibo Zhao; Haixiao Chen; An Qin; Peizhi Zhu
Journal:  Nanoscale Res Lett       Date:  2017-10-24       Impact factor: 4.703

10.  Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.

Authors:  Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Ewa Grzybowska
Journal:  Oncotarget       Date:  2016-10-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.